Skip to search formSkip to main contentSkip to account menu

BL-1020

Known as: BL 1020, BL1020 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Background/aims Cognitive impairment, which frequently occurs in patients with schizophrenia, bipolar disorder, Alzheimer’s… 
Review
2016
Review
2016
  • D. Mahmood
  • International Journal of Health Sciences
  • 2016
  • Corpus ID: 10215687
Histamine H3 receptors are present as autoreceptors on histaminergic neurons and as heteroreceptors on nonhistaminergic neurones… 
2012
2012
OBJECTIVE BL-1020 is a γ-aminobutyric acid (GABA)-enhanced antipsychotic that combines dopamine antagonism with GABA agonist… 
Review
2010
Review
2010
  • P. Fitzgerald
  • Current opinion in investigational drugs
  • 2010
  • Corpus ID: 27926085
In schizophrenia, a psychiatric disorder that affects approximately 1% of the global population and is associated with… 
2010
2010
Background:BL-1020, a novel gamma aminobutyric acid (GABA) ester of perphenazine, is a new oral antipsychotic with a strong… 
2009
2009
BL-1020 is a potentially novel antipsychotic, which comprises the typical antipsychotic perphenazine linked by an ester bound to…